DOCSLIB.ORG

Plaintiff's First Amended Complaint

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Plaintiff's First Amended Complaint Case 2:14-cv-00160-MCE-AC Document 10 Filed 02/21/14 Page 1 of 45 1 BURSOR & FISHER, P.A. L. Timothy Fisher (State Bar No. 191626) 2 Annick M. Persinger (State Bar No. 272996) 3 Julia A. Luster (State Bar No. 295031) 1990 North California Blvd., Suite 940 4 Walnut Creek, CA 94596 Telephone: (925) 300-4455 5 Facsimile: (925) 407-2700 E-Mail: [email protected] 6 [email protected] 7 [email protected] 8 Counsel for Plaintiff 9 10 UNITED STATES DISTRICT COURT 11 EASTERN DISTRICT OF CALIFORNIA 12 YESENIA MELGAR, on Behalf of Herself and Case No. 2:14-cv-00160-MCE-AC all Others Similarly Situated, 13 Plaintiff, FIRST AMENDED COMPLAINT 14 v. 15 JURY TRIAL DEMANDED ZICAM LLC and MATRIXX INITIATIVES, 16 INC. 17 Defendants. 18 19 20 21 22 23 24 25 26 27 28 FIRST AMENDED COMPLAINT CASE NO. 2:14-CV-00160-MCE-AC Case 2:14-cv-00160-MCE-AC Document 10 Filed 02/21/14 Page 2 of 45 1 Plaintiff Yesenia Melgar (“Plaintiff”), by her attorneys, makes the following allegations 2 pursuant to the investigation of her counsel and based upon information and belief, except as to 3 allegations specifically pertaining to herself and her counsel, which are based on personal 4 knowledge. 5 NATURE OF ACTION 6 1. This is a class action against Zicam LLC and Matrixx Initiatives, Inc. (collectively 7 “Defendants”) for falsely representing that the over-the-counter (“OTC”) homeopathic remedy 8 Zicam, “The Pre-Cold Medicine,” prevents, shortens, and reduces the severity of the symptoms of 9 the common cold. The Pre-Cold Medicine includes Zicam Pre-Cold RapidMelts Original, Zicam 10 Pre-Cold RapidMelts Ultra, Zicam Pre-Cold Oral Mist, Zicam Pre-Cold Ultra Crystals, Zicam Pre- 11 Cold Lozenges, Zicam Pre-Cold Lozenges Ultra, and Zicam Pre-Cold Chewables (“Pre-Cold 12 Medicine,” “Pre-Cold Products,” or “Products”). 13 2. Defendants falsely represent on Pre-Cold Medicine product labels and in their 14 nationwide advertising campaign that Zicam is “clinically proven to shorten cold,” “reduces 15 duration and severity of the common cold,” and “reduces severity of cold symptoms ▪ sore throat ▪ 16 stuffy nose ▪ sneezing ▪ coughing ▪ nasal congestion.” According to the sales pitch: “That first 17 sniffle, sneeze or throat tickle…you have a Pre-Cold™, the first sign a full blown cold is coming. 18 Take Zicam® now – clinically proven to shorten a cold. GO FROM PRE-COLD™ TO NO COLD 19 FASTER™.” In fact, Zicam Pre-Cold Products have only highly diluted concentrations of the 20 Products’ so-called “active ingredients” and are nothing more than placebos. 21 3. The dilution of the ingredients, zincum aceticum and zincum gluconicum, in 22 Defendants’ Pre-Cold Medicine renders those ingredients completely inactive. Since the 23 ingredients in the Pre-Cold Products have no pharmacological effect, the Products do not prevent 24 the common cold, are not “clinically shown to shorten cold,” do not “reduce[] duration of the 25 common cold,” and do not “reduce[] severity of cold symptoms ▪ sore throat ▪ stuffy nose ▪ 26 sneezing ▪ coughing ▪ nasal congestion.” 27 28 FIRST AMENDED COMPLAINT 1 CASE NO. 2:14-CV-00160-MCE-AC Case 2:14-cv-00160-MCE-AC Document 10 Filed 02/21/14 Page 3 of 45 1 4. As a direct and proximate result of Defendants’ false and misleading advertising 2 claims and marketing practices, Plaintiff and the members of the Class, as defined herein, 3 purchased Defendants’ ineffective Products. Plaintiff and the members of the Class purchased the 4 Pre-Cold Products because they were deceived into believing that the Products prevent, shorten, 5 and reduce the severity of the common cold. As a result, Plaintiff and members of the Class 6 purchased Zicam Pre-Cold Products that were not effective and have been injured in fact. Plaintiff 7 and the Class Members have suffered an ascertainable and out-of-pocket loss. Plaintiff and 8 members of the Class seek a refund and/or rescission of the transaction and all further equitable 9 and injunctive relief as provided by applicable law. 10 5. Plaintiff seeks relief in this action individually and on behalf of all purchasers of 11 Zicam Pre-Cold Products for violation of the Magnuson-Moss Warranty Act, 15 U.S.C. § 2301, et 12 seq., for breach of express and implied warranties, as well as for violation of the California 13 Consumer Legal Remedies Act (“CLRA”), Civil Code §§ 1750, et seq., California’s Unfair 14 Competition Law (“UCL”), Bus. & Prof. Code §§ 17200, et seq., and California’s False 15 Advertising Law (“FAL”), Bus. & Prof. Code §§ 17500, et seq. 16 THE PARTIES 17 6. Plaintiff Yesenia Melgar is a California citizen. 18 7. Zicam LLC is an Arizona Limited Liability Corporation with its principal place of 19 business at 8515 E. Anderson Drive, Scottsdale, AZ 85255. Zicam LLC is engaged in the business 20 of manufacturing, mass marketing, and distributing homeopathic formulas, including the Pre-Cold 21 Medicine, under the Zicam brand name. Zicam LLC is a wholly owned subsidiary of Defendant 22 Matrixx Initiatives, Inc. 23 8. Matrixx Initiatives, Inc. is a privately held corporation organized under the laws of 24 Delaware with its principal place of business located at 440 Rte. 22 East, 1 Grande Commons, 25 Suite 130, Bridgewater, New Jersey, 08807. Matrixx Initiatives, Inc. is engaged in the business of 26 manufacturing, mass marketing, and distributing homeopathic formulas, including the Pre-Cold 27 Medicine, under the Zicam brand name. Every Pre-Cold Product package states “©2012 28 FIRST AMENDED COMPLAINT 2 CASE NO. 2:14-CV-00160-MCE-AC Case 2:14-cv-00160-MCE-AC Document 10 Filed 02/21/14 Page 4 of 45 1 Distributed by Matrixx Initiatives, Inc.” Also, Matrixx Initiatives, Inc.’s website maintains that 2 Matrixx Initiatives, Inc. has “continuously developed and introduced Zicam cold shortening and 3 symptom-relieving products to the $6 billion cough/cold/allergy/sinus category.” 4 9. Defendants produce, market, and sell homeopathic products throughout the United 5 States. Defendants have long maintained substantial distribution and marketing operations in 6 California, and in this District. 7 10. Both of the Defendants acted jointly to perpetrate the acts described herein. At all 8 times relevant to the allegations in this matter, each Defendant acted in concert with, with the 9 knowledge and approval of, and/or as the agent of the other Defendant within the course and scope 10 of the agency, regarding the acts and omissions alleged. 11 JURISDICTION AND VENUE 12 11. This Court has subject matter jurisdiction under 28 U.S.C. § 1331 (federal question). 13 This Court has supplemental jurisdiction over state law claims pursuant to 28 U.S.C. § 1367. 14 12. This Court also has jurisdiction over this action pursuant to 28 U.S.C. § 1332(d) 15 because there are more than 100 Class Members, the aggregate amount in controversy exceeds 16 $5,000,000.00, exclusive of interest, fees, and costs, and at least one Class Member is a citizen of a 17 state different from at least one Defendant. 18 13. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because Defendants do 19 business throughout this District, Plaintiff purchased Zicam in this District, and the Products that 20 are the subject of the present Complaint are sold extensively in this District. 21 22 FACTUAL ALLEGATIONS COMMON TO ALL CLAIMS 23 A. The Homeopathic Formulation Of Zicam “The Pre-Cold Medicine” 24 14. All of the Pre-Cold Products contain homeopathic dilutions of zincum aceticum 25 (“zinc acetate”) and zincum gluconicum (“zinc gluconate”). 26 15. Zicam Pre-Cold RapidMelts, Zicam Pre-Cold Rapid Melts Ultra, Zicam Pre-Cold 27 Oral Mist, and Zicam Pre-Cold Crystals list zinc gluconate at a 1X dilution, which means that zinc 28 FIRST AMENDED COMPLAINT 3 CASE NO. 2:14-CV-00160-MCE-AC Case 2:14-cv-00160-MCE-AC Document 10 Filed 02/21/14 Page 5 of 45 1 gluconate is diluted in water to a ratio of 1 to 10, or 1/10th its original strength. Zinc acetate is 2 listed at a 2X dilution, which means it is diluted in water to a ratio of 1 to 100, or 1/100th of its 3 original strength. 4 16. Zicam Pre-Cold “Liqui-Loz,” Zicam Pre-Cold “Liqui-Loz,” and Zicam Pre-Cold 5 Chewables list both zinc acetate and zinc gluconate at a 2X dilution, meaning that the ingredients 6 have been diluted in water to a ratio of 1 to 100, or 1/100th of the ingredients’ original strength. 7 B. Zicam’s False And Misleading Labels 8 17. On its Pre-Cold Product labels, depicted below, Defendants make numerous false 9 and misleading marketing claims about the Products. Every Pre-Cold Product label bears the 10 misleading trademarked tagline: “GO FROM PRE-COLD™ TO NO COLD FASTER™.” The 11 message to consumers is clear: Zicam prevents colds. 12 13 14 15 16 17 18 19 20 21 22 23 24 18. The prefix “Pre” means “before.” Accordingly, the trademarked phrase “Pre-Cold” 25 denotes before-Cold. Indeed, the Products’ labels define “Pre-Cold™” as “That first sniffle, 26 sneeze or throat tickle…you have a Pre-Cold,™ the first sign a full blown cold is coming.” Thus, 27 28 FIRST AMENDED COMPLAINT 4 CASE NO. 2:14-CV-00160-MCE-AC Case 2:14-cv-00160-MCE-AC Document 10 Filed 02/21/14 Page 6 of 45 1 consumers are told that with Zicam Pre-Cold, they will stop a cold before it starts, and will get 2 “NO COLD.” However, Defendants’ message is false and misleading.
Load more

Recommended publications
  • Section 4: Business Institute of Bill of Rights Law at the William & Mary Law School
    College of William & Mary Law School William & Mary Law School Scholarship Repository Supreme Court Preview Conferences, Events, and Lectures 2010 Section 4: Business Institute of Bill of Rights Law at the William & Mary Law School Repository Citation Institute of Bill of Rights Law at the William & Mary Law School, "Section 4: Business" (2010). Supreme Court Preview. 198. https://scholarship.law.wm.edu/preview/198 Copyright c 2010 by the authors. This article is brought to you by the William & Mary Law School Scholarship Repository. https://scholarship.law.wm.edu/preview IV. Business In This Section: New Case: 09-152 Bruesewitz v. Wyeth, Inc. p. 107 Synopsis and Questions Presented p. 107 "SUPREME COURT ACCEPTS APPEAL OVER VACCINE SAFETY" p. 120 Bill Mears "3RD CIRCUIT: KIDS HURT BY VACCINES CAN'T PURSUE DESIGN DEFECT p. 122 CLAIMS" Shannon P. Duffy "VACCINE COURT FINDS No LINK TO AUTISM" p. 125 CN.com "SUIT SAYS MT. LEBANON GIRL SUFFERED SEVERE BRAIN DAMAGE" p. 128 Brian Bowling New Case: 09-329 Chase Bank USA, N.A. V. McCoy p. 130 Synopsis and Questions Presented p. 130 "SUPREME COURT TO HEAR JPMORGAN APPEAL IN CARD CASE" p. 141 James Vicini 7TH CIRCUIT RULES BANK CAN RAISE INTEREST RATE WITHOUT NOTICE p. 142 David Ziemer "BANK OF AMERICA WINS CREDIT CARD FEE LAWSUIT" p. 145 Jonathan Stempel "CREDIT CARD COMPANIES ADD TO ECONOMIC WOES" p. 146 Jann Swanson "CONSUMERS ARE DEALT A NEW HAND IN CREDIT CARDS" p. 148 Ron Lieber New Case: 08-1423 Costco Wholesale Corp. v. Omega, S.A. p. 150 Synopsis and Questions Presented p.
    [Show full text]
  • Zinc Toxicity in Odora Cells
    Zinc Toxicity in Odora Cells A thesis submitted to the University of Cincinnati Division of Graduate Studies in partial fulfillment of the requirements for the degree of Master of Science in the Department of Environmental Health of the College of Medicine by Heidi Hsieh A.B. Harvard University August 2011 Committee: Mary Beth Genter, Ph.D. (Chair) Hassane Amlal, Ph.D. Abstract Zinc has been touted as a panacea for the common cold. However, there has been some controversy over whether Zicam, an intranasal zinc gluconate gel purported to fight colds, causes anosmia, or the loss of the sense of smell. Historical evidence has shown that zinc sulfate solutions can cause anosmia in humans along with significant damage to the olfactory epithelium in rodents. However, more recent work has claimed to show that zinc gluconate is less toxic than zinc sulfate. Using an in vitro system to compare the toxicity of zinc sulfate and zinc gluconate on immature and mature rat olfactory sensory neurons, it was found that the toxicity of both zinc salts was similar with zinc sulfate being slightly more toxic than zinc gluconate and occurred at significantly lower concentrations than that found in Zicam nasal gel, which strengthens the epidemiological link between intranasal zinc exposure and anosmia. Mechanistic studies disproved the hypothesis that zinc toxicity was caused by inhibition of the HVCN1 proton channel which would have led to acidosis and apoptotic cell death. It was found that these immature rat olfactory sensory neurons are able to maintain their intracellular pH through a + + - - Na /H exchanger, specifically NHE1, and a Cl /HCO3 exchanger.
    [Show full text]
  • United States District Court Southern District of New York
    Case 7:15-cv-09843 Document 1 Filed 12/17/15 Page 1 of 32 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ALAN GULKIS, individually and on behalf of all others similarly situated, Plaintiff, CLASS ACTION COMPLAINT v. ZICAM LLC and MATRIXX INITIATIVES, JURY TRIAL DEMANDED INC. Defendants. Plaintiff Alan Gulkis (“Plaintiff”), by his attorneys, makes the following allegations pursuant to the investigation of his counsel and based upon information and belief, except as to allegations specifically pertaining to himself and his counsel, which are based on personal knowledge. NATURE OF ACTION 1. Defendants Zicam LLC and Matrixx Initiatives, Inc. (collectively “Defendants”) sell fake medicine to consumers seeking treatment for cold symptoms. Double-blind placebo- controlled trials show that Defendants’ “Zicam Pre-Cold Medicine” is nothing more than a placebo. Even though Defendants know that studies show that the “Pre-Cold Medicine” is no different than a placebo, Defendants represent that the “Pre-Cold Medicine” shortens and reduces the severity of cold symptoms, and that the “Pre-Cold Medicine” prevents full cold symptoms from occurring. Defendants have made millions of dollars selling dummy pills to New York residents. 2. Because Defendants’ Pre-Cold Medicine Products are mere placebos, Defendants’ representations that their Products shorten and reduce the severity of the common cold, as well as their representations that the Products stop full cold symptoms are false and misleading. The 1 Case 7:15-cv-09843 Document 1 Filed 12/17/15 Page 2 of 32 Pre-Cold Medicine includes Zicam Pre-Cold RapidMelts Original, Zicam Pre-Cold RapidMelts Ultra, Zicam Pre-Cold Oral Mist, Zicam Pre-Cold Ultra Crystals, Zicam Pre-Cold Lozenges, Zicam Pre-Cold Lozenges Ultra, and Zicam Pre-Cold Chewables (“Pre-Cold Medicine,” “Pre- Cold Products,” or “Products”).
    [Show full text]
  • ZICAM® COLD REMEDY Drug Facts
    ZICAM COLD REMEDY- galphimia glauca flowering top, luffa operculata fruit, and schoenocaulon officinale seed spray Matrixx Initiatives, Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- ZICAM® COLD REMEDY Drug Facts Active ingredients Galphimia glauca 4x, Luffa operculata 4x, Sabadilla 4x Purpose Reduces duration and severity of the common cold Uses reduces duration of the common cold reduces severity of cold symptoms: dry, scratchy throat runny nose watery eyes sneezing nasal congestion Zicam® Cold Remedy was formulated to shorten the duration of the common cold and may not be effective for flu or allergies. Warnings For nasal use only Do not use if you have a sensitivity or allergy to any of the ingredients. If an allergic reaction occurs, stop use and seek medical help right away. Ask a doctor before use if you have ear, nose, or throat sensitivity susceptibility to nosebleeds When using this product avoid contact with eyes. Rinse right away with water if it gets in eyes and seek medical help right away. the use of this container by more than one person may spread infection temporary discomfort such as burning, stinging, sneezing, or an increase in nasal discharge may occur Stop use and ask a doctor if symptoms get worse or last more than 7 days or are accompanied by fever redness or swelling is present new symptoms occur If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children.
    [Show full text]
  • Matrixx Initiatives, Inc. (Exact Name of Registrant As Specified in Its Charter) Delaware 87-0482806 (State Or Other Jurisdiction (I.R.S
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ¥ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2009 or n FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-31404 Matrixx Initiatives, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 87-0482806 (State or Other Jurisdiction (I.R.S. Employer of Incorporation or Organization) Identification No.) 8515 E. Anderson Drive Scottsdale, AZ 85255 602-385-8888 (Address of principal executive offices, Registrant’s Telephone Number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes n No ¥ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes n No ¥ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Reconciling Their Interests in Regulating Homeopathic Products, 49 J
    UIC Law Review Volume 49 Issue 4 Article 7 Summer 2016 The Food and Drug Administration Versus the Federal Trade Commission: Reconciling Their Interests in Regulating Homeopathic Products, 49 J. Marshall L. Rev. 1193 (2016) Jordannah Bangi Follow this and additional works at: https://repository.law.uic.edu/lawreview Part of the Administrative Law Commons, Antitrust and Trade Regulation Commons, and the Food and Drug Law Commons Recommended Citation Jordannah Bangi, The Food and Drug Administration Versus the Federal Trade Commission: Reconciling Their Interests in Regulating Homeopathic Products, 49 J. Marshall L. Rev. 1193 (2016) https://repository.law.uic.edu/lawreview/vol49/iss4/7 This Comments is brought to you for free and open access by UIC Law Open Access Repository. It has been accepted for inclusion in UIC Law Review by an authorized administrator of UIC Law Open Access Repository. For more information, please contact [email protected]. THE FOOD AND DRUG ADMINISTRATION VERSUS THE FEDERAL TRADE COMMISSION: RECONCILING THEIR INTERESTS IN REGULATING HOMEOPATHIC PRODUCTS JORDANNAH BANGI* I. THE POPULARITY AND GROWING SAFETY CONCERNS FOR HOMEOPATHIC PRODUCTS SPUR FDA AND FTC SCRUTINY ... 1194 II. HOMEOPATHY AND THE CONFLICT BETWEEN THE FDA AND THE FTC’S POLICIES ON REGULATING HOMEOPATHIC PRODUCTS ......................................................................... 1197 A. The Principles and Practice of Homeopathy ................ 1197 1. Basic Principles of Homeopathy ............................ 1197 2. Types of Homeopathic
    [Show full text]
  • Zicam® Cold Remedy Oral Mist™ Drug Facts
    ZICAM COLD REMEDY ORAL MIST- zinc acetate and zinc gluconate spray Matrixx Initiatives, Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- Zicam® Cold Remedy Oral Mist™ Drug Facts Active ingredients Zincum aceticum 2x Zincum gluconicum 1x Purpose Reduces duration and severity of the common cold Uses reduces duration of the common cold helps reduce severity of cold symptoms: sore throat stuffy nose sneezing coughing nasal congestion Zicam® Cold Remedy was formulated to shorten the duration of the common cold and was not formulated to be effective for flu or allergies. Warnings For oral use only Sore throat warning If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly. Ask a doctor before use if you have a sensitivity to zinc or are allergic to zinc When using this product avoid contact with eyes. Rinse right away with water if it gets in eyes and seek medical help right away. Stop use and ask a doctor if symptoms, including cough, persist, recur or are accompanied by a fever, rash, or persistent headache, or if new symptoms occur. A persistent cough that lasts for more than one week may be a sign of a serious condition. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
    [Show full text]
  • Siracusano V. Matrixx Initiatives
    FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT JAMES SIRACUSANO, Individually and on behalf of all others similarly situated, Plaintiff-Appellant, No. 06-15677 NECA-IBEW PENSION FUND, D.C. Nos. Claimant-Appellant, CV 04-0886 MHM CV 04-1012 MHM v. OPINION MATRIXX INITIATIVES, INC.; CARL J. JOHNSON; WILLIAM J. HEMELT, Defendants-Appellees. Appeal from the United States District Court for the District of Arizona Mary H. Murguia, District Judge, Presiding Argued and Submitted June 9, 2009—San Francisco, California Filed October 28, 2009 Before: Mary M. Schroeder, A. Wallace Tashima and Carlos T. Bea, Circuit Judges. Opinion by Judge Tashima 14507 14510 SIRACUSANO v. NECA-IBEW PENSION FUND COUNSEL Joseph D. Daley, Coughlin Stoia Geller Rudman & Robbins LLP, San Diego, California, for the plaintiff-appellant. Michael G. Yoder, O’Melveny & Myers LLP, Newport Beach, California, for the defendants-appellees. SIRACUSANO v. NECA-IBEW PENSION FUND 14511 OPINION TASHIMA, Circuit Judge: Matrixx Initiatives, Inc. (“Matrixx”) is a pharmaceutical company that sells cold products through its wholly-owned subsidiary, Zicam, LLC. One of its main products is Zicam Cold Remedy, which comes in several different forms.1 Plaintiffs-Appellants are lead plaintiff, NECA-IBEW Pension Fund, and named plaintiff, James Siracusano, in a class action brought against Matrixx and three Matrixx executives (collec- tively “Appellees”) under the Private Securities Litigation Reform Act of 1995 (“PSLRA”). Appellants alleged that Appellees violated the Securities Exchange Act of 1934 by failing to disclose material information regarding Zicam Cold Remedy — specifically, that Zicam causes a condition called anosmia, which is a loss of the sense of smell, in its users.
    [Show full text]
  • Zicam ® Cold Remedy Zinc and Elderberry Lozenge
    ZICAM COLD REMEDY ZINC AND ELDERBERRY LOZENGE- zinc acetate anhydrous, zinc gluconate, and sambucus nigra flowering top lozenge Church & Dwight Co., Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- Zicam ® Cold Remedy Zinc and Elderberry Lozenge Active ingredients (in each lozenge) Zincum aceticum 2x Zincum gluconicum 2x Sambucus nigra (elderberry) 4x Purpose Active ingredients (in each Purpose tablet) Zincum aceticum 2x Reduces duration of the common cold and helps relieve nasal congestion Zincum gluconicum 2x Sambucus nigra (elderberry) Helps relieve cold 4x symptoms * * Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Uses Reduces duration of the common cold and helps relieve nasal congestion ------------------------------------------------------------------------------------------------------ Zicam ® Cold Remedy was not formulated to be effective for flu and allergies. Warnings Sore throat warning: If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly. If you are allergic or sensitive to zinc, consult a doctor before using. Stop use and ask a doctor if symptoms, including cough, persist, recur or are accompanied by a fever, rash, or persistent headache, or if new symptoms occur. A persistent cough that lasts for more than one week may be a sign of a serious condition. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
    [Show full text]
  • Zicam® Cold Remedy Medicated Fruit Drops Drug Facts
    ZICAM COLD REMEDY MEDICATED FRUIT DROPS- zinc acetate anhydrous and zinc gluconate bar, chewable Matrixx Initiatives, Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- Zicam® Cold Remedy Medicated Fruit Drops Drug Facts Active ingredients (in each medicated drop) Zincum aceticum 2x Zincum gluconicum 2x Purpose Reduces duration and severity of the common cold Uses reduces duration of the common cold helps reduce severity of cold symptoms: sore throat stuffy nose sneezing coughing nasal congestion Zicam® Cold Remedy was formulated to shorten the duration of the common cold and was not formulated to be effective for flu or allergies. Warnings Ask a doctor before use if you have a sensitivity to zinc or are allergic to zinc Stop use and ask a doctor if symptoms persist or are accompanied by a fever or new symptoms occur If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Directions for best results, use at the first sign of a cold and continue to use until symptoms completely subside adults and children 12 years of age and older: take one medicated drop at onset of symptoms chew slowly and dissolve completely before swallowing repeat every 2 – 3 hours, not to exceed 5 medicated drops in 24 hours. Take until symptoms are gone. to avoid minor stomach upset, do not take on an empty stomach do not eat or drink for 15 minutes after use.
    [Show full text]
  • Timothy Hall, Et Al. V. Hemelt, Et Al. 09-CV-01899-Verified Shareholder
    Case 2:09-cv-01899-SRB Document 1 Filed 09/11/09 Page 1 of 19 1 Eric L. Zagar Robin Winchester 2 BARROWAY TOPAZ KESSLER MELTZER & CHECK, LLP 3 280 King of Prussia Road 4 Radnor, PA 19087 Telephone: (610) 667-7706 5 Fax: (610) 667-7056 [email protected] 6 [email protected] 7 Robert D. Mitchell, 011922 Julie M. Beauregard, 023093 Sarah K. Deutsch, 026229 8 MITCHELL & ASSOCIATES 9 A Professional Corporation Viad Corporate Center, Suite 1715 1850 North Central Avenue 10 Phoenix, Arizona 85004 Telephone (602) 468-1411 11 Fax (602) 468-1311 [email protected] 12 [email protected] [email protected] 13 www.mitchell-attorneys.com 14 Counsel for Plaintiff 15 UNITED STATES DISTRICT COURT 16 DISTRICT OF ARIZONA 17 TIMOTHY HALL, Derivatively on Behalf of ) 18 Nominal Defendant MATRIXX INITIATIVES, ) INC., ) 19 Plaintiff, ) Case No. 20 v. ) ) 21 WILLIAM J. HEMELT, SAMUEL C. ) COWLEY, CARL J. JOHNSON, L. WHITE) VERIFIED SHAREHOLDER 22 MATTHEWS, III, MICHAEL A. ZEHER,) DERIVATIVE COMPLAINT 23 WILLIAM C. EGAN, LORI H. BUSH, and ) JOHN M. CLAYTON, ) 24 Defendants, ) 25 ) and ) JURY TRIAL DEMANDED 26 ) MATRIXX INITIATIVES, INC., ) 27 ) 28 Nominal Defendant. ) ) Case 2:09-cv-01899-SRB Document 1 Filed 09/11/09 Page 2 of 19 1 Plaintiff Timothy Hall (“Plaintiff”), by the undersigned attorneys, submits this 2 Verified Shareholder Derivative Complaint (the “Complaint”) against the defendants named 3 herein, and alleges upon personal knowledge with respect to himself, and upon information 4 and belief based upon, inter alia, a review of public filings, press releases and reports, and an 5 investigation undertaken by Plaintiff’s counsel, as to all other allegations herein, as follows: 6 NATURE OF THE ACTION 7 1.
    [Show full text]
  • Zicam® Cold Remedy Rapidmelts® Citrus
    ZICAM COLD REMEDY RAPIDMELTS CITRUS- zinc acetate anhydrous and zinc gluconate tablet Matrixx Initiatives, Inc. Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. ---------- ® Zicam® Cold Remedy Rapidmelts Citrus Drug Facts Active ingredients (in each tablet) Zincum aceticum 2x Zincum gluconicum 1x Purpose Reduces duration and severity of the common cold Uses reduces duration of the common cold helps reduce severity of cold symptoms: sore throat stuffy nose sneezing coughing nasal congestion Zicam® Cold Remedy was formulated to shorten the duration of the common cold and was not formulated to be effective for flu or allergies. Warnings Ask a doctor before use if you have a sensitivity to zinc or are allergic to zinc Stop use and ask a doctor if symptoms persist or are accompanied by a fever or new symptoms occur If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Directions for best results, use at the first sign of a cold and continue to use until symptoms completely subside adults and children 12 years of age and older: take 1 tablet at the onset of symptoms dissolve entire tablet in mouth. Do not chew. Do not swallow whole. repeat every 2–3 hours, not to exceed 7 tablets in 24 hours. Take until symptoms are gone. to avoid minor stomach upset, do not take on an empty stomach do not eat or drink for 15 minutes after use.
    [Show full text]